Parkinson’s disease, a progressive neurological disorder affecting more than 166,000 people in the United Kingdom, may soon see a significant shift in treatment options, according to experts in the field. For years, available therapies have focused primarily on managing symptoms such as tremors, muscle stiffness, and slowed movement, without addressing the underlying progression of the disease. However, new developments suggest that disease-modifying drugs could become available within the next three years, potentially slowing or even halting Parkinson’s progression.
The advances stem from a deeper understanding of Parkinson’s pathology, including the role of abnormal clumps of the alpha synuclein protein, known as Lewy bodies, which accumulate in the brain and disrupt cellular function. This accumulation damages mitochondria, the energy-producing components of brain cells, leading to decreased dopamine production. Dopamine is critical for movement control, and its deficit results in the hallmark symptoms of Parkinson’s.
Currently, available treatments—including levodopa, dopamine agonists, and MAO-B inhibitors—offer symptom relief but do not alter disease course. More invasive options like deep brain stimulation are reserved for advanced stages. In contrast, several promising drugs, now in late-stage clinical trials, aim to interfere with disease mechanisms. Among these, prasinezumab, an antibody therapy targeting toxic alpha synuclein aggregates, has shown encouraging results in slowing motor symptom deterioration by up to 55% in an extended study. Though initial trials missed primary goals, further analyses suggest that the drug may significantly slow progression when used alongside levodopa, with final trial results expected by 2029.
Other compounds in phase III trials include ambroxol, a respiratory medication that boosts an enzyme involved in clearing alpha synuclein, and buntanetap, which reduces production of toxic brain proteins. Additionally, a major global study known as EJS ACT-PD is investigating three existing drugs—telmisartan, terazosin, and ursodeoxycholic acid—commonly prescribed for blood pressure, prostate enlargement, and liver conditions, respectively. Previous epidemiological data indicate that these drugs might lower Parkinson’s risk, although their effectiveness in treatment remains to be determined.
Early diagnosis is set to improve alongside these therapeutic advances. Researchers at University College London have developed a blood test capable of detecting protein patterns linked to Parkinson’s up to seven years before clinical symptoms appear. This could facilitate earlier intervention, potentially increasing the efficacy of disease-modifying treatments.
Meanwhile, symptom management drugs are also evolving. Tavapadon, a once-daily pill stimulating select dopamine receptors, is under review by U.S. regulators and may offer fewer side effects like compulsive behaviors commonly associated with current dopamine agonists. Additionally, adaptive deep brain stimulation, which automatically adjusts stimulation to control tremors, is being introduced within the National Health Service. Trials are also underway testing ondansetron, a drug already used to treat chemotherapy-induced nausea, for its potential to reduce hallucinations affecting many Parkinson’s patients.
Experts emphasize that while challenges remain, these developments represent an unprecedented period of progress in Parkinson’s research. Professor David Dexter of Imperial College London highlights that some individuals identified with early biological signs may never develop full symptoms with timely intervention. Professor Miratul Muqit of the University of Edinburgh echoes the cautious optimism, noting the advances in understanding disease mechanisms provide a valuable framework for drug development.
Patients like Anna Edwards, diagnosed at age 51 and participating in ongoing trials, express guarded hope. Diagnosed after noticing early symptoms, Edwards is encouraged by the prospect of treatments that could slow disease progression and improve quality of life.
With Parkinson’s cases rising rapidly both in the UK and globally, these breakthroughs offer a promising path toward more effective therapies and improved outcomes for millions affected by the disease.